{"pmid":32304394,"title":"First successful treatment of COVID-19 induced refractory cardiogenic plus vasoplegic shock by combination of pVAD and ECMO - a case report.","text":["First successful treatment of COVID-19 induced refractory cardiogenic plus vasoplegic shock by combination of pVAD and ECMO - a case report.","The novel coronavirus SARS-CoV-2 is infecting hundreds of thousands of humans around the globe. The coronavirus disease COVID-19 is known to generate mild as well as critical courses. Complications on the intensive care units include acute respiratory distress syndrome, acute cardiac- and kidney injury as well as shock.Here, we present the first case report of a successful treatment of a COVID-19 patient presenting with ARDS plus refractory combined cardiogenic and vasoplegic shock, which could be successfully stabilized after implantation of a percutaneous ventricular assist device (pVAD) plus an extracorporeal membrane oxygenation (ECMO).While such intense treatment might not be feasible in case of a health care disaster as described for the hot spots of the COVID-19 pandemic, it might encourage treatment of younger patients on intensive care units not overcrowded by critically ill patients.","ASAIO J","Bemtgen, Xavier","Kruger, Kirsten","Supady, Alexander","Durschmied, Daniel","Schibilsky, David","Bamberg, Fabian","Bode, Christoph","Wengenmayer, Tobias","Staudacher, Dawid L","32304394"],"abstract":["The novel coronavirus SARS-CoV-2 is infecting hundreds of thousands of humans around the globe. The coronavirus disease COVID-19 is known to generate mild as well as critical courses. Complications on the intensive care units include acute respiratory distress syndrome, acute cardiac- and kidney injury as well as shock.Here, we present the first case report of a successful treatment of a COVID-19 patient presenting with ARDS plus refractory combined cardiogenic and vasoplegic shock, which could be successfully stabilized after implantation of a percutaneous ventricular assist device (pVAD) plus an extracorporeal membrane oxygenation (ECMO).While such intense treatment might not be feasible in case of a health care disaster as described for the hot spots of the COVID-19 pandemic, it might encourage treatment of younger patients on intensive care units not overcrowded by critically ill patients."],"journal":"ASAIO J","authors":["Bemtgen, Xavier","Kruger, Kirsten","Supady, Alexander","Durschmied, Daniel","Schibilsky, David","Bamberg, Fabian","Bode, Christoph","Wengenmayer, Tobias","Staudacher, Dawid L"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304394","week":"202016|Apr 13 - Apr 19","doi":"10.1097/MAT.0000000000001178","source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664431720445771776,"score":8.233237,"similar":[{"pmid":32275347,"title":"Myocardial localization of coronavirus in COVID-19 cardiogenic shock.","text":["Myocardial localization of coronavirus in COVID-19 cardiogenic shock.","We describe the first case of acute cardiac injury directly linked to myocardial localization of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in a 69-year-old patient with flu-like symptoms rapidly degenerating into respiratory distress, hypotension, and cardiogenic shock. The patient was successfully treated with venous-arterial extracorporeal membrane oxygenation (ECMO) and mechanical ventilation. Cardiac function fully recovered in 5 days and ECMO was removed. Endomyocardial biopsy demonstrated low-grade myocardial inflammation and viral particles in the myocardium suggesting either a viraemic phase or, alternatively, infected macrophage migration from the lung. This article is protected by copyright. All rights reserved.","Eur J Heart Fail","Tavazzi, Guido","Pellegrini, Carlo","Maurelli, Marco","Belliato, Mirko","Sciutti, Fabio","Bottazzi, Andrea","Sepe, Paola Alessandra","Resasco, Tullia","Camporotondo, Rita","Bruno, Raffaele","Baldanti, Fausto","Paolucci, Stefania","Pelenghi, Stefano","Iotti, Giorgio Antonio","Mojoli, Francesco","Arbustini, Eloisa","32275347"],"abstract":["We describe the first case of acute cardiac injury directly linked to myocardial localization of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in a 69-year-old patient with flu-like symptoms rapidly degenerating into respiratory distress, hypotension, and cardiogenic shock. The patient was successfully treated with venous-arterial extracorporeal membrane oxygenation (ECMO) and mechanical ventilation. Cardiac function fully recovered in 5 days and ECMO was removed. Endomyocardial biopsy demonstrated low-grade myocardial inflammation and viral particles in the myocardium suggesting either a viraemic phase or, alternatively, infected macrophage migration from the lung. This article is protected by copyright. All rights reserved."],"journal":"Eur J Heart Fail","authors":["Tavazzi, Guido","Pellegrini, Carlo","Maurelli, Marco","Belliato, Mirko","Sciutti, Fabio","Bottazzi, Andrea","Sepe, Paola Alessandra","Resasco, Tullia","Camporotondo, Rita","Bruno, Raffaele","Baldanti, Fausto","Paolucci, Stefania","Pelenghi, Stefano","Iotti, Giorgio Antonio","Mojoli, Francesco","Arbustini, Eloisa"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275347","week":"202015|Apr 06 - Apr 12","doi":"10.1002/ejhf.1828","keywords":["Cardiac injury","Cardiogenic shock","Coronavirus","Extracorporeal membrane oxygenation","Myocardial inflammation","SARS-Cov-2"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1663712077953368064,"score":436.3537},{"pmid":32271455,"title":"Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report.","text":["Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report.","Since the end of 2019, COVID-19 has been prevalent in Wuhan, China, and has been rapidly spreading to mainland China. Currently, more than 80,000 people have been infected, of which over 10,000 were severely ill and had characteristics of dyspnea and hypoxemia about one week after onset. Severe patients had rapidly progressed to acute respiratory distress syndrome (ARDS), causing multiple organ failures and even death, with a mortality rate of nearly 4.3%. The treatment of severe COVID-19 patients has been rarely reported. This study reported a successful example of a severe COVID-19 patient with extracorporeal membrane oxygenation (ECMO) technology in our hospital. This experience revealed that the early application of ECMO can dramatically promote the recovery of severe COVID-19 patients.","Eur Rev Med Pharmacol Sci","Zhan, W-Q","Li, M-D","Xu, M","Lu, Y-B","32271455"],"abstract":["Since the end of 2019, COVID-19 has been prevalent in Wuhan, China, and has been rapidly spreading to mainland China. Currently, more than 80,000 people have been infected, of which over 10,000 were severely ill and had characteristics of dyspnea and hypoxemia about one week after onset. Severe patients had rapidly progressed to acute respiratory distress syndrome (ARDS), causing multiple organ failures and even death, with a mortality rate of nearly 4.3%. The treatment of severe COVID-19 patients has been rarely reported. This study reported a successful example of a severe COVID-19 patient with extracorporeal membrane oxygenation (ECMO) technology in our hospital. This experience revealed that the early application of ECMO can dramatically promote the recovery of severe COVID-19 patients."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Zhan, W-Q","Li, M-D","Xu, M","Lu, Y-B"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32271455","week":"202015|Apr 06 - Apr 12","doi":"10.26355/eurrev_202003_20705","source":"PubMed","locations":["China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1663620083100942336,"score":286.776},{"pmid":32203711,"pmcid":"PMC7102637","title":"Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.","text":["Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.","WHO interim guidelines recommend offering extracorporeal membrane oxygenation (ECMO) to eligible patients with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The number of patients with COVID-19 infection who might develop severe ARDS that is refractory to maximal medical management and require this level of support is currently unknown. Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO. The need for ECMO is relatively low and its use is mostly restricted to specialised centres globally. Providing complex therapies such as ECMO during outbreaks of emerging infectious diseases has unique challenges. Careful planning, judicious resource allocation, and training of personnel to provide complex therapeutic interventions while adhering to strict infection control measures are all crucial components of an ECMO action plan. ECMO can be initiated in specialist centres, or patients can receive ECMO during transportation from a centre that is not specialised for this procedure to an expert ECMO centre. Ensuring that systems enable safe and coordinated movement of critically ill patients, staff, and equipment is important to improve ECMO access. ECMO preparedness for the COVID-19 pandemic is important in view of the high transmission rate of the virus and respiratory-related mortality.","Lancet Respir Med","Ramanathan, Kollengode","Antognini, David","Combes, Alain","Paden, Matthew","Zakhary, Bishoy","Ogino, Mark","MacLaren, Graeme","Brodie, Daniel","Shekar, Kiran","32203711"],"abstract":["WHO interim guidelines recommend offering extracorporeal membrane oxygenation (ECMO) to eligible patients with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The number of patients with COVID-19 infection who might develop severe ARDS that is refractory to maximal medical management and require this level of support is currently unknown. Available evidence from similar patient populations suggests that carefully selected patients with severe ARDS who do not benefit from conventional treatment might be successfully supported with venovenous ECMO. The need for ECMO is relatively low and its use is mostly restricted to specialised centres globally. Providing complex therapies such as ECMO during outbreaks of emerging infectious diseases has unique challenges. Careful planning, judicious resource allocation, and training of personnel to provide complex therapeutic interventions while adhering to strict infection control measures are all crucial components of an ECMO action plan. ECMO can be initiated in specialist centres, or patients can receive ECMO during transportation from a centre that is not specialised for this procedure to an expert ECMO centre. Ensuring that systems enable safe and coordinated movement of critically ill patients, staff, and equipment is important to improve ECMO access. ECMO preparedness for the COVID-19 pandemic is important in view of the high transmission rate of the virus and respiratory-related mortality."],"journal":"Lancet Respir Med","authors":["Ramanathan, Kollengode","Antognini, David","Combes, Alain","Paden, Matthew","Zakhary, Bishoy","Ogino, Mark","MacLaren, Graeme","Brodie, Daniel","Shekar, Kiran"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32203711","week":"202013|Mar 23 - Mar 29","doi":"10.1016/S2213-2600(20)30121-1","source":"PubMed","topics":["Prevention","Treatment"],"weight":1,"_version_":1663352133666209792,"score":277.12628},{"pmid":32304395,"title":"COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support.","text":["COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support.","The outbreak of novel coronavirus (SARS-CoV-2) which causes the respiratory illness COVID-19 has led to unprecedented efforts at containment due to its rapid community spread, associated mortality, and lack of immunization and treatment. We herein detail a case of a young patient who suffered life-threatening disease and multi-organ failure. His clinical course involved rapid and profound respiratory decompensation such that he required support with veno-venous extracorporeal membrane oxygenation (VV-ECMO). He also demonstrated hyperinflammation (C-reactive protein peak 444.6 mg/L) with severe cytokine elevation (Interleukin-6 peak > 3,000 pg/mL). Through treatment targeting hyperinflammation he recovered from critical COVID-19 respiratory failure and required only 160 hours of VV-ECMO support. He is currently extubated without an oxygen requirement, showing signs of renal recovery on intermittent hemodialysis, and his repeat SARS-CoV-2 test is negative 21 days after his first positive test. We present the first successful case of VV-ECMO support to recovery of COVID-19 respiratory failure in North America.","ASAIO J","Hartman, Matthew E","Hernandez, Roland A","Patel, Krish","Wagner, Teresa E","Trinh, Tony","Lipke, Anne B","Yim, Eric T","Pulido, Juan N","Pagel, John M","Youssef, Samuel J","Mignone, John L","32304395"],"abstract":["The outbreak of novel coronavirus (SARS-CoV-2) which causes the respiratory illness COVID-19 has led to unprecedented efforts at containment due to its rapid community spread, associated mortality, and lack of immunization and treatment. We herein detail a case of a young patient who suffered life-threatening disease and multi-organ failure. His clinical course involved rapid and profound respiratory decompensation such that he required support with veno-venous extracorporeal membrane oxygenation (VV-ECMO). He also demonstrated hyperinflammation (C-reactive protein peak 444.6 mg/L) with severe cytokine elevation (Interleukin-6 peak > 3,000 pg/mL). Through treatment targeting hyperinflammation he recovered from critical COVID-19 respiratory failure and required only 160 hours of VV-ECMO support. He is currently extubated without an oxygen requirement, showing signs of renal recovery on intermittent hemodialysis, and his repeat SARS-CoV-2 test is negative 21 days after his first positive test. We present the first successful case of VV-ECMO support to recovery of COVID-19 respiratory failure in North America."],"journal":"ASAIO J","authors":["Hartman, Matthew E","Hernandez, Roland A","Patel, Krish","Wagner, Teresa E","Trinh, Tony","Lipke, Anne B","Yim, Eric T","Pulido, Juan N","Pagel, John M","Youssef, Samuel J","Mignone, John L"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304395","week":"202016|Apr 13 - Apr 19","doi":"10.1097/MAT.0000000000001177","source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664431720422703104,"score":264.25513},{"pmid":32251794,"title":"Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?","text":["Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged since December 2019 in Wuhan city, and has quickly spread throughout China and other countries. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. According to World Health Organization (WHO), management of coronavirus disease 19 (COVID-19) has mainly focused on infection prevention, case detection and monitoring, and supportive care. Given to the previous experience, extracorporeal membrane oxygenation (ECMO) has been proven to be an effective therapy in the treatment of respiratory failure or acute respiratory distress syndrome (ARDS). On the basis of similar principle, ECMO may be also an effective therapy in the treatment of severe COVID-19. In this study, we described and discussed the clinical outcomes of ECMO for ARDS patients, ECMO use for severe COVID-19 in China, the indications of ECMO use, and some important issues associated with ECMO.","Int J Infect Dis","Hong, Xiaoyang","Xiong, Jing","Feng, Zhichun","Shi, Yuan","32251794"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged since December 2019 in Wuhan city, and has quickly spread throughout China and other countries. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. According to World Health Organization (WHO), management of coronavirus disease 19 (COVID-19) has mainly focused on infection prevention, case detection and monitoring, and supportive care. Given to the previous experience, extracorporeal membrane oxygenation (ECMO) has been proven to be an effective therapy in the treatment of respiratory failure or acute respiratory distress syndrome (ARDS). On the basis of similar principle, ECMO may be also an effective therapy in the treatment of severe COVID-19. In this study, we described and discussed the clinical outcomes of ECMO for ARDS patients, ECMO use for severe COVID-19 in China, the indications of ECMO use, and some important issues associated with ECMO."],"journal":"Int J Infect Dis","authors":["Hong, Xiaoyang","Xiong, Jing","Feng, Zhichun","Shi, Yuan"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251794","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.ijid.2020.03.058","keywords":["acute respiratory distress syndrome","coronavirus disease 19","extracorporeal membrane oxygenation","respiratory failure"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352136203763712,"score":256.30646}]}